Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive ALCL or ALK-positive unresectable IMT

Document first published:: 16 July 2026
Page updated:: 21 August 2026
Topic:: Specialised commissioning
Publication type:: Policy or strategy, Report

Crizotinib is not recommended to be available as a routinely commissioned treatment option for patients with relapsed or refractory ALK-positive ALCL or ALK-positive unresectable IMT.

Document

$Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) or ALK-positive unresectable inflammatory myofibroblastic tumour (IMT)$

Clinical commissioning policy: Crizotinib for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) or ALK-positive unresectable inflammatory myofibroblastic tumour (IMT)

PDF
210 KB
5 pages

Summary

PDF format. Published 16 July 2026.

Document

$CPAG summary report: Crizotinib for patients with relapsed or refractory ALK-positive ALCL or ALK-positive unresectable IMT$